Zhenbaodao Pharmaceutical's Strategic Investment in ADC New Drug Receives Clinical Trial Approval

Source: @Securities Market Red Weekly Weibo

Recently, by AdcorisAdcorisProviding platform technical support, the Nectin4-targeted ADC project, LNF2105 for injection, jointly developed with Shandong New Era Pharmaceutical Co., Ltd. of Lunan Pharmaceutical Group, has officially received the drug clinical trial approval notice issued by the National Medical Products Administration (NMPA).

The implementation of this important achievement not only marks a new phase in the technical cooperation between Adcoris and Lunan Pharmaceutical but also highlightsZBDThe foresight and effectiveness of ZBD Pharmaceutical's strategic investments in the innovative drug sector have added significant weight to the company’s R&D layout, which focuses on "traditional Chinese medicine as the mainstay, with coordinated development in chemical and biological drugs."

As a leading traditional Chinese medicine enterprise with 30 years of dedication to the pharmaceutical and healthcare field, ZBD Pharmaceutical has consistently adhered to its corporate mission of "providing high-quality health products and services to the world." It has established a diversified R&D layout centered on traditional Chinese medicine while integrating chemical and biopharmaceuticals, forming an innovation-driven development model powered by both independent research and strategic investment. The recently approved clinical trial for LNF2105 for injection focuses on the Nectin4 target, which is highly expressed in various malignant solid tumors and represents a significant direction in targeted cancer therapy. The development and application of related ADC drugs will bring new treatment hope to patients with advanced solid tumors.

In the development of this project, Adcoris relied on its proprietary ADC technology platform and a full set of technologies including highly active cytotoxins (Drug), elastomeric cleavable linkers (Linker), and precise conjugation technology to complete the design and development of this innovative ADC drug.

Notably, as early as 2021, ZBD Pharmaceutical's "Shizhen Fund" made a strategic investment in Adcoris. The core technology platform capabilities of this company have already been authoritatively validated. The recent approval for clinical trials of injectable LNF2105 is a significant outcome of this strategic investment, achieving a two-way win of research results and investment returns. It also confirms ZBD Pharmaceutical's precise judgment in the investment and layout of innovative drug fields.

It is reported that the "ZBD Fund" is an important carrier for ZBD Pharmaceutical to implement the dual-driven strategy of "industry + capital". It aims to focus on high-quality targets with value and potential in the pharmaceutical health field. Through financial support and industrial empowerment, it helps invested enterprises break through technical bottlenecks and accelerate the transformation of achievements. At the same time, it promotes the diversification and upgrading of its own R&D layout, achieving coordinated development of the industrial chain. The approval of the ADC project developed by Adcoris not only broadens the layout boundary of ZBD Pharmaceutical in the biopharmaceutical field but also lays a solid foundation for the company's continuous efforts in the innovative drug track.

For a long time, ZBD Pharmaceutical has steadily ranked amongChina MedicineAmong the top 100 industrial enterprises and the top 20 Chinese medicine enterprises in China, a "one heart, three institutes" product innovation R&D system has been established. While deeply cultivating its core business of traditional Chinese medicine (TCM), the company actively expands into cutting-edge fields such as chemical drugs and biopharmaceuticals. By combining independent R&D with strategic investments, it continuously enhances its product pipeline and strengthens its core competitiveness. The recent approval for clinical trials of LNF2105 for injection marks not only a successful implementation of the company's strategic investment but also a vivid realization of its R&D development strategy. This demonstrates the company’s commitment and responsibility to promoting pharmaceutical innovation and safeguarding public health.

In the future, ZBD Pharmaceutical will continue to uphold the development philosophy of "platform, cooperation, sharing, and win-win," further deepen its innovative R&D layout. On one hand, it will focus on the traditional Chinese medicine (TCM) field, inheriting and innovating the essence of TCM; on the other hand, it will increase investment and R&D efforts in cutting-edge areas such as chemical drugs and biopharmaceuticals. Relying on platforms like the "ZBD Fund," it will empower more high-quality innovative enterprises and projects, accelerating the implementation of pharmaceutical innovation achievements. This will inject new momentum into the high-quality development of China's pharmaceuticals and healthcare industry, providing the public with better and more efficient health products and services.

Disclaimer: This article is for reference only and does not constitute investment advice.